Status:
COMPLETED
Reactive Oxygen Species in the Pathogenesis of Diabetic Complications
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Juvenile Diabetes Research Foundation
National Institutes of Health (NIH)
Conditions:
Type 1 Diabetes
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy and incipient nephropathy in these models. In cultured vascular cells, it also reduces a...
Detailed Description
The glycemic status of study patients was assessed by measuring baseline values of HbA1c, fructosamine, and fasting plasma glucose. Mean HbA1c was 8.7+ 0.7%, mean fructosamine was 421+29 mg/dl (normal...
Eligibility Criteria
Inclusion
- Male
- Type 1 diabetes duration between zero and fifteen years
- current insulin therapy
Exclusion
- Female
- proliferative retinopathy
- microalbuminuria
- symptomatic diabetic neuropathy
- cardiovascular disease
- taking medications
- smoking
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00703989
Start Date
February 1 2005
End Date
February 1 2008
Last Update
November 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GCRC, Albert Einstein College of Medicine
The Bronx, New York, United States, 10461